Ivonescimab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer, Cervical Cancer
Trial Timeline
Apr 4, 2025 → Apr 4, 2027
NCT ID
NCT06925724About Ivonescimab
Ivonescimab is a phase 2 stage product being developed by Summit Therapeutics for Endometrial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06925724. Target conditions include Endometrial Cancer, Cervical Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07234877 | Phase 2 | Recruiting |
| NCT07094685 | Phase 2 | Recruiting |
| NCT06959550 | Phase 2 | Recruiting |
| NCT06980077 | Phase 2 | Recruiting |
| NCT06940518 | Phase 2 | Recruiting |
| NCT06840834 | Phase 2 | Recruiting |
| NCT06925724 | Phase 2 | Recruiting |
| NCT06805617 | Phase 2 | Recruiting |
| NCT06672575 | Phase 1/2 | Recruiting |
| NCT06567314 | Phase 2 | Recruiting |
Competing Products
20 competing products in Endometrial Cancer